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Activation of c-junN-terminal kinase (JNK) signaling is
associated with neuronal cell death. As described in
this issue of Chemistry & Biology, cell-based screen-
ing efforts yielded a compound, AEG3482, which inter-
acts with heat shock protein 90 leading to inhibition of
JNK and blockade of neuronal apoptosis [1].
Neurodegenerative diseases, including Parkinson’s and
Alzheimer’s disease, are characterized by the progres-
sive dysfunction and loss of disease-specific classes
of neurons. Although these diseases afflict millions, cur-
rent treatments largely ameliorate symptoms rather than
halt disease progression. The majority of neurodegener-
ative diseases are associated with the formation of pro-
tein deposits [2]. Tau-containing neurofibrillary tangles
and b-amyloid-containing plaques are characteristic
of Alzheimer’s, whereas a-synuclein-containing Lewy
bodies are found in Parkinson’s. In Huntington’s and
related diseases, polyglutamine-expanded proteins
form aggregates. Hsp70 is the chaperone most com-
monly found in these intracellular inclusions. Protein
chaperones may protect against progression of these
diseases by promoting the formation of less toxic pro-
tein aggregates and/or by targeting toxic, misfolded
proteins for degradation through the ubiquitin-protea-
some system.
Interruption of neuronal cell death pathways may halt
the progression of neurodegenerative diseases. A major
event in neuronal apoptosis is activation of the JNK sig-
naling pathway and, indeed, pathological specimens
from Alzheimer’s disease, as well as samples from
mouse models of Alzheimer’s and Huntington’s disease,
reveal activated JNK [3–5]. A well-studied model of JNK-
mediated neuronal apoptosis involves deprivation of
nerve growth factor (NGF) [5]. In response to NGF with-
drawal, JNK is activated through upstream kinases and/
or GTPases through a pathway that remains to be com-
pletely defined. Activated JNK phosphorylates the tran-
scription factor c-jun leading to induction of proapo-
ptotic members of the Bcl-2 family. Some of these Bcl-2
family members are also direct substrates of JNK. Proa-
poptotic Bcl-2 family members facilitate the release of
cytochrome c (as well as other proapoptotic factors)
from the intermembrane space of the mitochondria
into the cytosol leading to activation of caspases, key
proteases involved in cellular destruction.
Because of the important role of JNK in neuronal apo-
ptosis, selective kinase inhibitors that target the ATP
binding site of JNK and its activating kinases, including
the mixed lineage kinases (MLKs), are being vigorously
pursued as potential therapeutic agents [3–5]. In the cur-
rent study, high throughput screening of a chemical li-
brary of 17,000 compounds for small molecules that
block NGF withdrawal-induced, JNK-dependent apo-ptosis of primary sympathetic neurons has led to the
identification of an imidazothiadiazole sulfonamide,
designated AEG3482, as a potential neuroprotective
agent [1]. Indeed Salehi et al. found that AEG3482 in-
hibited JNK-mediated phosphorylation of c-jun, cas-
pase-3 cleavage and activation, and cell death in several
cell-based models of JNK-dependent apoptosis, point-
ing to JNK inhibition as its primary mode of action [1].
However, extended treatment times were required for
AEG3482 efficacy; and AEG3482 was unable to block
JNK activity in vitro, indicating an indirect means of
blocking JNK activation that likely involved transcription
and translation of an endogenous JNK inhibitor.
Barker and colleagues hypothesized that AEG3482
may suppress JNK-mediated apoptosis through induc-
tion of Hsp70 [1]. Hsp70 has been documented to inhibit
JNK by binding JNK and disrupting substrate interac-
tions and/or by stabilizing the phosphatases that would
normally inactivate JNK (reviewed by Meriin and Sher-
man [2]) In accord with this mechanism, AEG3482 treat-
ment increased mRNA and protein levels of Hsp70 [1].
Expression of the Hsp70 gene is controlled by the tran-
scription factor heat shock factor 1 (HSF1). HSF1 is
kept in a latent, cytosolic form through its interactions
with yet another chaperone, termed Hsp90. In response
to cellular stresses, HSF1 is released from Hsp90, trans-
locates to the nucleus, and activates transcription [6].
Further experimentation demonstrated that AEG3482 in-
duced the transcriptional activity of an Hsp70 promoter
construct in an HSF1-dependent manner; and multiple
lines of evidence point to Hsp70 induction as the means
by which AEG3482 blocks apoptosis. The ability of
AEG3482-conjugated Sepharose beads to bind purified
Hsp90 argues that Hsp90 is its direct target. The aggre-
gate of evidence suggests that AEG3482 protects
against neuronal cell death by binding to and inducing
a conformational change in Hsp90, leading to HSF1 re-
lease and transcriptional activation of Hsp70, which, in
turn, blocks JNK activation.
Hsp90 is an abundant, homodimeric molecular chap-
erone that, in addition to sequestration of HSF1, acts to
chaperone steroid hormone receptors and, when in
complex with the cochaperone Cdc37, certain protein
kinases [7]. The majority of Hsp90 inhibitors, including
geldanamycin (GA) and its derivatives, inhibit ATPase
activity by competing with nucleotide binding in the N-
terminal domain, leading to destabilization and protea-
some-mediated degradation of chaperone substrates
[8]. Chaperone substrates of Hsp90 include prosurvival
and oncogenic kinases like Akt, cyclin-dependent ki-
nases, Raf, and Her2/neu, providing the rationale for ex-
ploring Hsp90 inhibitors as anticancer agents; and the
GA derivative, 17-allylamino-17-demethoxygeldanamy-
cin (17-AAG), is currently in cancer clinical trials [9].
The work of Barker and colleagues is particularly
interesting because it suggests that Hsp90, already
a target for cancer treatment, may be a viable target
for the development of neuroprotective agents. A recent
flurry of research activity supports the concept that
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against neurotoxic insults in a variety of models of neu-
rodegenerative disease [10–15]. For instance, GA treat-
ment protects against the neurotoxic effects of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a mouse
model of Parkinson’s disease [14]; and 17-AAG amelio-
rates neuronal degeneration in a mouse model of the
polyglutamine expansion disease spinal and bulbar
muscular atrophy (SBMA) [15]. In each of these cases,
the classic Hsp90 inhibitors, induce Hsp70 production
through activation of HSF1 similar to what was observed
for AEG3482. Although JNK activation status was not
assessed, it is quite possible that JNK inhibition could
contribute to the observed neuroprotective effect.
Interestingly, geldanamycin fails to compete with
AEG3482 for Hsp90 binding, suggesting that AEG3482
may not bind through the N-terminal ATPase domain.
Furthermore, AEG3482 did not destabilize the prosur-
vival kinase Akt as geldanamycin does [1, 16], which
could certainly be an added benefit in the development
of neuroprotective agents. It will be interesting to deter-
mine the effect of AEG3482 on other Hsp90/Cdc37
chaperone substrates, including MLK3 [17], which has
been implicated in JNK-dependent apoptosis, and
the Leucine rich repeat kinase 2 (Lrrk2) [18], which is
mutated in a significant fraction of familial Parkinson’s
disease.
Intriguing data from both the cancer and neurobiology
fields suggests that Hsp90 inhibitors may act selectively
in pathological cells, sparing normal cells. Despite the
ubiquitous, abundant expression of Hsp90, 17-AAG
preferentially accumulates in tumor cells as compared
with normal cells, consistent with the finding that
17-AAG binds more tightly to the Hsp90 conformer pres-
ent in activated supermolecular chaperone complexes
of tumor cells than to the latent Hsp90 dimer present in
normal cells [19–21]. In an a-synuclein-induced model
of neurotoxicity in fruit flies, GA elevated Hsp70 levels
in stressed cells but not in neighboring healthy cells
[11]. This may suggest that in the neuropathological
state, the chaperone-mediated stress response may be
primed for response to Hsp90 inhibitors; and that com-
pounds, such as AEG3482, may be selective neuro-
protective agents. It will be important to now assess the
efficacy of AEG3482 and related compounds in animal
models of neurodegenerative disease. This exciting
work of Barker and colleagues, along with other recent
findings, suggests that targeting Hsp90 and the stress
response may be a promising therapeutic approach for
the treatment of diverse neurodegenerative diseases.Kathleen A. Gallo1
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